This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Staging of endometrial cancer

Authoring team

Endometrium carcinoma is generally staged according to the International Federation of Gynecology and Obstetrics (FIGO)

Revised (2009) FIGO staging of endometrial cancer:

  • stage I -confined to the corpus uteri
    • I A - no myometrial invasion or less than half
    • I B - invasion equal to or more than half the myometrium
  • stage II - tumour invades cervical stroma but does not extend beyond uterus
  • stage III - local and/or regional spread of the tumour
    • III A - tumour invades serosa of corpus uteri and/or adnexae
    • III B - vaginal and/or parametrial involvement
    • III C - metastases to pelvic and/or para-aortic lymph nodes
    • III C1 - positive pelvic nodes
    • III C2 - positive para-aortic lymph nodes with or without positive pelvic
  • stage IV – tumour invades bladder and/or bowel mucosa and/or distant metastases
    • IVA - tumour invasion of bladder and/or bowel mucosa
    • IV B - distant metastases, including intra-abdominal metastases and/or inguinal lymph nodes

Furthermore cases of carcinoma of the corpus should be grouped with regard to the degree of differentiation of the adenocarcinoma as follows:

  • G1: <5% of a nonsquamous or nonmorular solid growth pattern
  • G2: 6%–50% of a nonsquamous or nonmorular solid growth pattern
  • G3: >50% of a nonsquamous or nonmorular solid growth pattern (2)

Note:

  • notable nuclear atypia (pleomorphism and prominent nucleoli), inappropriate for the architectural grade, raises the grade of a Grade 1 or Grade 2 tumor by 1
  • in serous and clear cell adenocarcinomas, nuclear grading takes precedent. Most authors consider serous and clear cell carcinomas high grade by definition

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.